Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMGN NYSE:BMY NASDAQ:EXEL NASDAQ:GILD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$331.57+0.2%$347.53$267.83▼$391.29$178.50B0.442.73 million shs4.07 million shsBMYBristol Myers Squibb$58.45+0.2%$58.53$42.52▼$62.89$119.07B0.2610.30 million shs8.55 million shsEXELExelixis$49.90+2.5%$44.77$33.76▼$51.63$12.23B0.382.94 million shs2.41 million shsGILDGilead Sciences$130.69+0.1%$137.18$104.46▼$157.29$162.02B0.316.24 million shs5.57 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+1.96%-1.65%-6.91%-12.90%+19.90%BMYBristol Myers Squibb+1.63%+3.15%-3.28%-2.65%+23.33%EXELExelixis-2.35%-1.60%+8.42%+9.44%+8.91%GILDGilead Sciences+0.64%-3.29%-5.19%-14.56%+22.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$331.57+0.2%$347.53$267.83▼$391.29$178.50B0.442.73 million shs4.07 million shsBMYBristol Myers Squibb$58.45+0.2%$58.53$42.52▼$62.89$119.07B0.2610.30 million shs8.55 million shsEXELExelixis$49.90+2.5%$44.77$33.76▼$51.63$12.23B0.382.94 million shs2.41 million shsGILDGilead Sciences$130.69+0.1%$137.18$104.46▼$157.29$162.02B0.316.24 million shs5.57 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+1.96%-1.65%-6.91%-12.90%+19.90%BMYBristol Myers Squibb+1.63%+3.15%-3.28%-2.65%+23.33%EXELExelixis-2.35%-1.60%+8.42%+9.44%+8.91%GILDGilead Sciences+0.64%-3.29%-5.19%-14.56%+22.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMGNAmgen 2.48Hold$355.197.12% UpsideBMYBristol Myers Squibb 2.37Hold$61.314.89% UpsideEXELExelixis 2.39Hold$47.35-5.10% DownsideGILDGilead Sciences 2.86Moderate Buy$156.9320.07% UpsideCurrent Analyst Ratings BreakdownLatest BMY, AMGN, EXEL, and GILD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026AMGNAmgen ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$400.00 ➝ $375.005/20/2026GILDGilead Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$165.005/19/2026GILDGilead Sciences Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$161.00 ➝ $150.005/14/2026AMGNAmgen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$432.00 ➝ $427.005/13/2026AMGNAmgen Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$410.00 ➝ $390.005/11/2026GILDGilead Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/11/2026GILDGilead Sciences Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$170.00 ➝ $167.005/8/2026GILDGilead Sciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$175.00 ➝ $168.005/8/2026GILDGilead Sciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$148.00 ➝ $146.005/8/2026GILDGilead Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$155.00 ➝ $157.005/8/2026GILDGilead Sciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$123.00 ➝ $122.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMGNAmgen$36.75B4.87$33.90 per share9.78$17.03 per share19.47BMYBristol Myers Squibb$48.19B2.48$8.15 per share7.17$9.84 per share5.94EXELExelixis$2.32B5.41$3.10 per share16.08$7.70 per share6.48GILDGilead Sciences$29.44B5.51$10.49 per share12.46$18.87 per share6.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMGNAmgen$7.71B$14.3714.9714.073.3220.96%137.41%13.28%8/4/2026 (Estimated)BMYBristol Myers Squibb$7.05B$3.569.839.630.1715.01%64.87%13.16%7/30/2026 (Estimated)EXELExelixis$782.57M$3.0116.2813.521.0335.08%39.89%30.23%8/4/2026 (Estimated)GILDGilead Sciences$8.51B$7.3415.5913.59N/A30.99%48.19%18.28%8/6/2026 (Estimated)Latest BMY, AMGN, EXEL, and GILD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026GILDGilead Sciences$1.91$2.03+$0.12$1.61$6.91 billion$6.96 billion5/5/2026Q1 2026EXELExelixis$0.75$0.87+$0.12$0.8138$607.51 million$610.81 million4/30/2026Q1 2026AMGNAmgen$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion4/30/2026Q1 2026BMYBristol Myers Squibb$1.42$1.58+$0.16$1.31$10.93 billion$11.49 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMGNAmgen$10.083.04%+8.27%70.15%14 YearsBMYBristol Myers Squibb$2.524.31%+1.61%70.79%17 YearsEXELExelixisN/AN/AN/AN/AN/AGILDGilead Sciences$3.282.52%+3.04%44.69%10 YearsLatest BMY, AMGN, EXEL, and GILD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GILDGilead Sciencesquarterly$0.822.45%6/15/20266/15/20266/29/20263/4/2026AMGNAmgenquarterly$2.523.09%5/15/20265/15/20266/5/20263/2/2026BMYBristol Myers Squibbquarterly$0.634.23%4/2/20264/2/20265/1/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMGNAmgen5.651.261.01BMYBristol Myers Squibb2.101.421.28EXELExelixisN/A3.263.19GILDGilead Sciences0.891.971.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMGNAmgen76.50%BMYBristol Myers Squibb76.41%EXELExelixis85.27%GILDGilead Sciences83.67%Insider OwnershipCompanyInsider OwnershipAMGNAmgen0.85%BMYBristol Myers Squibb0.05%EXELExelixis2.60%GILDGilead Sciences0.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMGNAmgen31,500539.68 million535.10 millionOptionableBMYBristol Myers Squibb32,5002.04 billion2.04 billionOptionableEXELExelixis1,077251.35 million244.82 millionOptionableGILDGilead Sciences17,0001.24 billion1.24 billionOptionableBMY, AMGN, EXEL, and GILD HeadlinesRecent News About These CompaniesGilead Sciences Launches New $3 Billion Senior Notes2 hours ago | tipranks.comCigna downgraded, Humana upgraded: Wall Street's top analyst callsMay 20 at 10:09 AM | finance.yahoo.comGilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on ItMay 20 at 10:01 AM | zacks.comGilead Sciences (NASDAQ:GILD) Upgraded to Buy at Maxim GroupMay 20 at 9:04 AM | marketbeat.comGilead Sciences, Inc. $GILD Shares Sold by Mitsubishi UFJ Asset Management UK Ltd.May 20 at 5:42 AM | marketbeat.comJag Capital Management LLC Buys New Stake in Gilead Sciences, Inc. $GILDMay 20 at 5:42 AM | marketbeat.comFideuram Intesa Sanpaolo Private Banking S.P.A. Takes $50.80 Million Position in Gilead Sciences, Inc. $GILDMay 20 at 3:54 AM | marketbeat.comGilead Sciences, Inc. $GILD Shares Sold by Banque Cantonale VaudoiseMay 20 at 3:19 AM | marketbeat.comAtle Fund Management AB Sells 27,373 Shares of Gilead Sciences, Inc. $GILDMay 20 at 3:11 AM | marketbeat.com5 Best Long Term Low Risk Stocks to Buy According to Hedge FundsMay 19 at 3:31 PM | insidermonkey.comGilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 2:00 PM | seekingalpha.comDaiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock PriceMay 19 at 10:34 AM | marketbeat.com3 Market-Beating Stocks to Research FurtherMay 19 at 7:18 AM | finance.yahoo.comPolymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and PfizerMay 19 at 7:18 AM | finance.yahoo.comResona Asset Management Co. Ltd. Lowers Stake in Gilead Sciences, Inc. $GILDMay 19 at 6:43 AM | marketbeat.comProfund Advisors LLC Buys 15,824 Shares of Gilead Sciences, Inc. $GILDMay 19 at 6:18 AM | marketbeat.comProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILDMay 19 at 6:18 AM | marketbeat.comGilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 28,000 Shares of StockMay 19 at 4:44 AM | americanbankingnews.comGilead Sciences (NASDAQ:GILD) CFO Sells $396,810.00 in StockMay 19 at 4:35 AM | insidertrades.comHandelsbanken Fonder AB Sells 81,694 Shares of Gilead Sciences, Inc. $GILDMay 19 at 4:22 AM | marketbeat.comHighTower Advisors LLC Decreases Stake in Gilead Sciences, Inc. $GILDMay 19 at 4:12 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMY, AMGN, EXEL, and GILD Company DescriptionsAmgen NASDAQ:AMGN$331.57 +0.82 (+0.25%) Closing price 04:00 PM EasternExtended Trading$331.25 -0.32 (-0.10%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.Bristol Myers Squibb NYSE:BMY$58.45 +0.14 (+0.25%) Closing price 03:59 PM EasternExtended Trading$58.42 -0.03 (-0.05%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.Exelixis NASDAQ:EXEL$49.90 +1.23 (+2.53%) Closing price 04:00 PM EasternExtended Trading$49.31 -0.59 (-1.19%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.Gilead Sciences NASDAQ:GILD$130.69 +0.19 (+0.15%) Closing price 04:00 PM EasternExtended Trading$130.10 -0.59 (-0.45%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
